CP 220629
Latest Information Update: 19 Jul 2002
Price :
$50 *
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 21 Mar 2000 Profile reviewed but no significant changes made
- 22 May 1998 New profile